A new era of therapy for hepatitis C virus infection

Current Opinion in Infectious Diseases

Volumn 28, Issue 5, 2015, Pages 471-478

  Nyalakonda, Harita ^a   Utay, Netanya S ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

antiviral therapy; direct acting antivirals; hepatitis C virus; interferon free

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; REINFECTION; REVIEW; DRUG EFFECTS; HEPACIVIRUS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84948682797     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000190     Document Type: Review

References (64)

1. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. J Am Med Assoc. 2014; 312: 631-640.
2. Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014; 20: 9633-9652.
3. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011; 31: 1090-1101.
4. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57: 1333-1342.
5. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among subjects with chronic hepatitis C and advanced hepatic fibrosis. J Am Med Assoc. 2012; 308: 2584-2593.
6. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015; 385: 1124-1135.
7. Manns MP, Mchutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958-965.
8. Fried M, Shiffman M, Reddy R, et al. Pedinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-982.
9. Jacobson I, Mchutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-2416.
10. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infections. N Engl J Med. 2011; 364: 1195-1206.
11. Bacon B, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207-1217.
12. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417-2428.
13. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naïve subjects: the COSMOS randomized study. Lancet. 2014; 384: 1756-1765.
14. Fontaine H, Hezode C, Zoulim F, et al. Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the French observational cohort ANRS C022 Hepathe. [Abstract LP28]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015.
15. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1889-1898.
16. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated genotype 1 infection. N Engl J Med. 2014; 370: 1483-1493.
17. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370: 1879-1888.
18. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat subjects with HCV genotype 1 infection and cirrhosis nonresponsive to previous protease-inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015; 15: 397-404.
19. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAD SYNERGY trial [Abstract 240]. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA; 7-11 November 2014.
20. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in subjects with HCV genotype 1 and HIV co-infection. J Am Med Assoc. 2015; 313: 1232-1239.
21. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for subjects with HCV genotype 3 or 6 infection [Abstract LB11]. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA; 7-11 November 2014.
22. Hezode C, Asselah T, Reddy K R, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced subjects with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized, open-label trial. Lancet. 2015; 385: 2502-2509.
23. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced subjects with HCV genotype 1b infection. Gastroenterology. 2014; 147: 359-365.
24. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983-1992.
25. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin.NEngl JMed. 2014; 370: 1594-1603.
26. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1604-1614.
27. Sulkowski MS, Ron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in subjects co-infected with HIV-1: a randomized trial. J Am Med Assoc. 2015; 313: 1223-1231.
28. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370: 1973-1982.
29. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370: 211-221.
30. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in the HCV genotype 1-mono-infected patients from the French observational cohort ANRS Co22 Hepather [Abstract L03]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015.
31. Poordad E, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study [Abstract L08]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015.
32. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in subjects with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61: 1127-1135.
33. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384: 1597-1605.
34. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366: 216-224.
35. Poordad F, Sievert W, Mollison L, et al. All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir for noncirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR12 results [Abstract LB7]. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA; 7-11 November 2014.
36. Muir AJ, Poordad F, Lalezari JP, et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir, /- ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results [Abstract LB2]. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA; 7-11 November 2014.
37. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomized, open-label phase 2 trial. Lancet. 2015; 385: 1087-1097.
38. Lawitz E,Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomized, open-label phase 2 trial. Lancet. 2015; 385: 1075-1086.
39. Kwo P, Gane E, Peng C-Y, et al. Efficacy and safety of grazoprevir/elbasvir / RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial [Abstract P0886]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015.
40. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1-13.
41. Brown A, Hezode C, Zuckerman E, et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir and elbasvir with or without ribavirin in patients with HCV GT2, 4, 5 or 6 infection [Abstract P0771]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015.
42. Poordad E, Lawitz E, Gutierrez JA, et al. C-SWIFT: Grazoprevir/elbasvir s sofosbuvir in cirrhotic and noncirrhotic, treatment-naïve patients with hepatitis C virus genotype 1 infection, for durations of 4, 6, or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks [Abstract O006]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015
43. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-1887.
44. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in subjects without treatment options. N Engl J Med. 2013; 368: 1867-1877.
45. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370: 1993-2001.
46. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in subjects co-infected with HIV (PHOTON-2): a multicenter, open-label, nonrandomised, phase 3 study. Lancet. 2015; 385: 1098-1106.
47. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis Cvirus infection in subjects of Egyptian ancestry. J Hepatol. 2015; 62: 1040-1046.
48. Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol. 2014; 28: 445-451.
49. Koh C, Liang TJ. What is the future of ribavirin therapy for hepatitis C?. Antiviral Res. 2014; 104: 34-39.
50. Keating GM. Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015; 75: 675-685.
51. Reddy KJ, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in subjects with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015; 62: 79-86.
52. Sulkowski MS. Management of acute and chronic HCV infection in persons with HIV coinfection. J Hepatol. 2014; 61 (1 Suppl): S108-S119.
53. Rockstroh JK. Optimal therapy of HIV/HCV co-infected subjects with direct acting antivirals. Liver Int. 2015; 35 (Suppl 1): 51-55.
54. Coppola N, Martini S, Pisaturo M, et al. Treatment of chronic hepatitis C in subjects with HIV/HCV coinfection. World J Virol. 2015; 4: 1-12.
55. Burgess S, Partovi N, Yoshida EM, et al. A review of drug interactions with direct-Acting antivirals for hepatitis C: implications for HIV and transplant subjects. Ann Pharmacother. 2015; 49: 674-687.
56. Kaur K, Gandhi MA, Slish J, et al. Drug-drug interactions among hepatitis C virus (HCV) and human immunodeficiency virus (HIV) medications. Infect Dis Ther. 2015; 4: 159-172.
57. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013; 57 (2 Suppl): S105-S110.
58. Martin TC,Martin NK, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013; 27: 2551-2557.
59. Ingiliz P, Krznaric I, Stellbrink HJ, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med. 2014; 15: 355-361.
60. Ornstein C. New hepatitis C drugs are costing Medicare billions. The Washington Post [Internet]. March 29, 2015 [Cited May 4, 2015]; Health& Science. http://www.washingtonpost.com/national/health-science/med icare-spent-45-billion-on-new-hepatitis-c-drugs-last-year-data-shows/.2015/03/29/66952dde-d32a-11e4-A62f-ee745911a4ff-story.html
61. Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected subjects. J Viral Hepat 2015. [Epub ahead of print
62. Leidner AJ, Chesson HW, Ward JW, et al. Cost-effectiveness of hepatitis C treatment for subjects in early stages of liver disease. Hepatology. 2015; 61: 1860-1869.
63. Johnson SJ, Misurski DA, Juday TR, et al. Cost-effectiveness of treating different stages of genotype 1 hepatitis C virus (HCV) with AbbVie 3D (ABT-450/ritonavir/ombitasvir and dasabuvir) with or without ribavirin compared to no treatment in the United States [Abstract P0815]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 22-26 April 2015.
64. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015; 162: 407-419.